Waschbusch, Max http://orcid.org/0000-0002-3281-3538
Rodriguez, Lisa
Brueckner, Andreas
Lee, Kerry Jo
Li, Xuefeng
Mokliatchouk, Oksana
Tremmel, Lothar
Yuan, Shuai S.
Article History
Accepted: 2 June 2022
First Online: 3 July 2022
Declarations
:
: Except for editorial and writing support, no funding was provided for this article.
: WM and TL are employed by CSL Behring. BA, MO, and YS are employed by Novartis, Biogen and Kite Pharma, respectively. BA holds Novartis shares. They have no other conflicts to disclose. This publication reflects the views of the authors and should not be construed to represent their employers’ views or policies. RL, LKJ, and LX are employed by the US FDA. They have no other conflicts to disclose. This article reflects the views of the authors and should not be construed to reflect the FDA's views or policies.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: Not applicable.
: WM, RL, BA, LK, LX, MO, TL, and YS substantially contributed to all aspects of authorship, including conception and design, data acquisition, analysis, and interpretation; drafting and revising the work; final approval of the published version; and agreement to be accountable for all aspects of the work.